Effectiveness of Lenvatinib Versus Sorafenib for Unresectable Hepatocellular Carcinoma in Patients with Hepatic Decompensation.
Min Kyung ParkYun Bin LeeHyemi MoonNa Ryung ChoiMinseok Albert KimHeejoon JangJoon Yeul NamEun Ju ChoJeong-Hoon LeeSu Jong YuYoon Jun KimJung-Hwan YoonPublished in: Digestive diseases and sciences (2022)
The effectiveness of lenvatinib and sorafenib was comparable for the treatment of unresectable HCC in decompensated patients.